New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:02 EDTAMGN, AZNAmgen, AstraZeneca reports brodalumab study met primary, secondary endpoints
Amgen (AMGN) and AstraZeneca (AZN) announced that the Phase 3 AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the interleukin-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index, and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.
News For AMGN;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:00 EDTAZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Outperform from Market Perform at Cowen... Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Citi... Alliance Resource Partners (ARLP) upgraded to Buy from Hold at Deutsche Bank... ArcBest (ARCB) upgraded to Peer Perform from Underperform at Wolfe Research... AstraZeneca (AZN) upgraded to Buy from Hold at Berenberg... ConAgra (CAG) upgraded to Overweight from Equal Weight at Morgan Stanley... DuPont Fabros (DFT) upgraded to Buy from Neutral at Citi... EastGroup Properties (EGP) upgraded to Buy from Neutral at Citi... Galaxy Entertainment (GXYEY) upgraded to Hold from Sell at Deutsche Bank... GrubHub (GRUB) upgraded to Outperform from Sector Perform at RBC Capital... HealthSouth (HLS) upgraded to Outperform from Market Perform at JMP Securities... IGM Financial (IGIFF) upgraded to Sector Performer from Underperformer at CIBC... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Kimco Realty (KIM) upgraded to Buy from Neutral at Citi... Kosmos (KOS) upgraded to Outperform at BMO Capital... MGM China (MCHVF) upgraded to Hold from Sell at Deutsche Bank... Regal Entertainment (RGC) upgraded to Neutral from Sell at B. Riley... SL Green Realty (SLG) upgraded to Buy from Neutral at Citi... SQM (SQM) upgraded to Buy from Hold at HSBC... Sands China (SCHYY) upgraded to Hold from Sell at Deutsche Bank... Terex (TEX) upgraded to Neutral from Underperform at BofA/Merrill... United Community Banks (UCBI) upgraded to Outperform from Market Perform at Raymond James... Weingarten Realty (WRI) upgraded to Buy from Neutral at Citi... Willis Group (WSH) upgraded to Neutral from Sell at Goldman... Wynn Macau (WYNMF) upgraded to Hold from Sell at Deutsche Bank.
05:30 EDTAZNAstraZeneca upgraded to Buy from Hold at Berenberg
Subscribe for More Information
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
10:19 EDTAZNAstraZeneca, Eolas Therapeutics partner on EORA program for smoking cessation
Eolas Therapeutics said that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics grant from the National Institutes of Health for the development of the program from the preclinical stage through phase I clinical trials. The total deal potential is in excess of $145M. This includes upfront, clinical and regulatory milestone payments. Additionally, Eolas is eligible to receive royalties on commercial sales.
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 29, 2015
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
June 24, 2015
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 19, 2015
16:02 EDTAMGNAmgen presents open-label extension data for Phase 2 study of migraine treatment
Subscribe for More Information
07:23 EDTAMGNTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use